Immunogenic synthetic glycoconjugate for the immunotherapy of melanoma
US9255156B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 18, 2014 |
| Grant date | Feb 9, 2016 |
| Priority date | — |
| Expiry date | Feb 18, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A specific antibody against a compound of formula (I)wherein X is O, NH, S, CH2; L is a linker that is a divalent spacer; A is an adjuvant or carrier that is an immunogenic molecule or an immunogenic particle; and wherein bonds between linker and saccharide moiety and between linker and carrier are of covalent type; wherein the linker L presents a chemical structure suitable to space the saccharide moiety and the carrier by 7-30 atoms when the adjuvant/carrier A is a biomacromolecule or by 19-30 atoms when the adjuvant/carrier A is a metallic nanoparticle; wherein the carrier/adjuvant A can be selected among a macromolecule, a macrocycle, a dendrimer, a liposome, a nanoparticle, an oligosaccharide featuring from two to five monosaccharidic units or cells like dendritic cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.